Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

11.98
+0.48004.17%
Post-market: 11.85-0.1300-1.09%19:05 EDT
Volume:1.12M
Turnover:13.21M
Market Cap:966.97M
PE:-4.42
High:11.99
Open:11.73
Low:11.52
Close:11.50
52wk High:14.91
52wk Low:3.91
Shares:80.72M
Float Shares:54.46M
Volume Ratio:0.83
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7110
EPS(LYR):-2.3246
ROE:-73.95%
ROA:-37.79%
PB:3.93
PE(LYR):-5.15

Loading ...

EyePoint Pharmaceuticals Inc : Mizuho Raises Target Price to $28 From $26

THOMSON REUTERS
·
Aug 15

Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating

MT Newswires Live
·
Aug 15

EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Stock Track | EyePoint Pharmaceuticals Plunges 5.88% Pre-Market on Disappointing Q2 Results and Increased Losses

Stock Track
·
Aug 06

Stock Track | EyePoint Pharmaceuticals Plunges 5.88% Pre-Market on Q2 Revenue Miss and Widening Losses

Stock Track
·
Aug 06

EyePoint Q2 revenue falls 44%, net loss widens

Reuters
·
Aug 06

EyePoint Pharmaceuticals Q2 EPS $(0.85) Misses $(0.81) Estimate, Sales $5.333M Miss $6.627M Estimate

Benzinga
·
Aug 06

EyePoint Pharmaceuticals Q2 Product Sales USD 5.333 Million

THOMSON REUTERS
·
Aug 06

EyePoint Pharmaceuticals Inc - Topline Data for Lugano Expected Mid-2026

THOMSON REUTERS
·
Aug 06

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire
·
Aug 06

EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a share - Earnings Preview

Reuters
·
Aug 04

EyePoint Pharmaceuticals Inc - Topline Data for Lugano Expected Mid-2026

THOMSON REUTERS
·
Jul 29

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

GlobeNewswire
·
Jul 29

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 16

EyePoint Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 20

RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target

MT Newswires Live
·
Jun 17

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
May 30

BRIEF-Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration

Reuters
·
May 27

Karen L. Zaderej, Director, Reports Acquisition of Common Shares in EyePoint Pharmaceuticals Inc

Reuters
·
May 20

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating

MT Newswires Live
·
May 16